Impact of comorbidities on the severity of chronic hepatitis B at presentation

Evangelista Sagnelli1, Tommaso Stroffolini, Alfonso Mele

  • 1Department of Public Medicine, Section of Infectious Diseases, Second University of Naples, 80132 Naples, Italy. evangelista.sagnelli@unina2.it

Insights

Older age, hepatitis D virus (HDV) infection, and alcohol abuse significantly increase the risk of severe liver disease in chronic hepatitis B patients. Hepatitis C virus (HCV) infection plays a lesser role.

Area of Science:

  • Hepatology
  • Virology
  • Clinical Medicine

Background:

  • Chronic hepatitis B (CHB) is a significant global health concern.
  • Co-infections and lifestyle factors can influence the clinical presentation and severity of CHB.
  • Understanding these cofactors is crucial for effective patient management.

Purpose of the Study:

  • To assess the clinical relevance of various cofactors in patients with chronic hepatitis B.
  • To identify independent predictors of severe liver disease in CHB patients.

Main Methods:

  • A cohort of 1366 hepatitis B surface antigen (HBsAg)-positive individuals was analyzed.
  • Patients were categorized based on cofactors: hepatitis D virus (HDV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), alcohol abuse, multiple cofactors, or cofactor-free (CF).
  • Clinical data, including age, geographic residence, and presence of cirrhosis, were compared across groups using univariate and multivariate analyses.

Main Results:

  • Alcohol abuse and HDV infection were associated with older age and higher rates of cirrhosis compared to the CF group.
  • HCV infection was also linked to older age and cirrhosis.
  • Multivariate analysis confirmed older age, heavy alcohol consumption (>8 drinks/day), and HDV positivity as independent predictors of liver cirrhosis. HCV positivity was not an independent predictor in multivariate analysis.

Conclusions:

  • Older age, HDV infection, and alcohol abuse are key determinants of severe liver disease in chronic HBV infection.
  • HCV replication appears to have a less significant role in the severity of liver damage compared to HDV and alcohol abuse.
Abstract

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...